CEP-18770

Brand Name:
Generic Name:
Code Name: CEP-18770
Company: Cephalon
FDA Clinical Phase: preclinical

Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that CEP-18770 demonstrated superior activity to Velcade (bortezomib), and it caused fewer side effects during treatment.

Clinical Trials:
Currently, there are not yet any clinical trials studying CEP-18770 for multiple myeloma.

Updated November 14, 2009

Related Articles:

Leave a comment

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.